Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study [0.03%]
肾脏一站式检查评估门诊(COSMIC)：可行性研究
Chiara Re,James P Blackmur,Teele Kuusk et al.
Chiara Re et al.
Background and objective: Our aim was to evaluate the feasibility and outcomes of a one-stop renal mass biopsy (RMB) clinic at which same-day biopsy results were facilitated by the use of confocal microscopy. ...
The Conundrum of Intermediate Risk in Localised Prostate Cancer: One Group, Many Realities [0.03%]
局部前列腺癌Intermediate Risk困境：一个群体，多种现实
Arthur Peyrottes,Guillaume Ploussard,Paul Sargos et al.
Arthur Peyrottes et al.
For intermediate-risk prostate cancer, definitions remain inconsistent and management varies. Greater precision is urgently needed via optimal use of existing tools and integration of emerging innovations to harmonise care and improve outco...
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group [0.03%]
国际膀胱癌组关于 intermediate-risk 低级非肌层浸润性膀胱癌的定义、危险度分层、治疗策略及临床试验设计的指导意见
Roger Li,Patrick J Hensley,Marko Babjuk et al.
Roger Li et al.
Background and objective: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease, and standardized definitions and risk-guided management are critical for appropriate patient care and...
The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA Detection in Muscle-invasive Bladder Cancer [0.03%]
肌层浸润性膀胱癌中肾脏、肝脏功能及免疫状态对循环肿瘤DNA检测的影响
Deema Radif,Sia Viborg Lindskrog,Iver Nordentoft et al.
Deema Radif et al.
Background and objective: The kidneys and liver play key roles in the metabolism of circulating molecules, including nucleic acids. To advance the clinical utility of circulating tumor DNA (ctDNA), it is essential to exam...
Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial [0.03%]
[177Lu]Lu-PSMA-617治疗转移性透明细胞肾细胞癌患者的疗效：多中心、单臂、Ⅱ期RENALUT试验
Emmanuel Seront,Mehdi Bsilat,Karolien Goffin et al.
Emmanuel Seront et al.
Background and objective: Angiogenesis-targeting tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) are standard treatments for metastatic clear-cell renal cell carcinoma (ccRCC). However, therapeut...
Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer [0.03%]
顺铂适合型肌侵袭性膀胱癌的新辅助化疗的再评价
Javier Molina-Cerrillo,James Catto,Ashish M Kamat et al.
Javier Molina-Cerrillo et al.
Background and objective: Management of muscle-invasive bladder cancer (MIBC) is evolving rapidly due to advances in systemic therapies and molecular understanding. Neoadjuvant cisplatin-based chemotherapy remains the cor...
Prognostic Implications of Very High Decipher Scores in Prostate Cancer: Towards a Refined Genomic Risk Classification [0.03%]
前列腺癌的极高Decipher评分预后意义：迈向精确的基因组风险分类
Rohan Sharma,Marcio C Moschovas,Seetharam K R Bhatt et al.
Rohan Sharma et al.
Background and objective: The 22-gene Decipher genomic classifier (DGC) is validated for risk stratification in prostate cancer. Our aim was to evaluate the association of a novel very high-risk (VHR) group (DGC score >0....
Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis [0.03%]
转移性激素敏感型前列腺癌的治疗路径：来自PIONEER+大数据分析的结论
Rossella Nicoletti,Alex Qinyang Liu,Susan Evans-Axelsson et al.
Rossella Nicoletti et al.
Background and objective: The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) is evolving rapidly. Real-world data (RWD) are essential to understand actual treatment use and outcomes. This stu...
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis [0.03%]
卡巴他赛对比阿比特龙或恩杂鲁胺治疗多西他赛治疗后预后不良的转移性去势抵抗性前列腺癌患者：一项Ⅱ期研究联合循环肿瘤DNA分析
Karan Parekh,Kim van der Zande,Sarah W S Ng et al.
Karan Parekh et al.
Background and objective: Whether cabazitaxel or an androgen receptor pathway inhibitor (ARPI) is the optimal treatment option for poor-prognosis metastatic castration-resistant prostate cancer (mCRPC), progressing on doc...
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN [0.03%]
阿帕鲁胺治疗高瘤负荷转移性激素敏感性前列腺癌患者的疗效和安全性：TITAN研究亚组分析
Alejo Rodriguez-Vida,Angel Borque,Fernando Lopez-Campos et al.
Alejo Rodriguez-Vida et al.
Background and objective: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with hi...